Tolterodine

被引：119

作者：

Hills C.J. ^{[1
]}

Winter S.A. ^{[1
]}

Balfour J.A. ^{[1
]}

Abrams P. ^{[1
]}

Brenner B. ^{[1
]}

机构：

[1] Adis International Limited, Private Bag 65901, Mairangi Bay, Auckland 10

来源：

Drugs | 1998年 / 55卷 / 6期

关键词：

Adis International Limited; Overactive Bladder; Oxybutynin; Urge Incontinence; Tolterodine;

D O I：

10.2165/00003495-199855060-00008

中图分类号：

学科分类号：

摘要：

Tolterodine is a competitive muscarinic receptor antagonist which has recently been launched for the treatment of overactive bladder. Tolterodine shows functional selectivity for the bladder over the salivary glands in vivo, which is not attributable to muscarinic receptor subtype selectivity. It is as potent as oxybutynin in inhibiting bladder contraction, but is much less potent in inhibiting salivation, suggesting that it may have less propensity to cause dry mouth in clinical use. In patients with overactive bladder, tolterodine significantly reduces the frequency of micturition and number of incontinence episodes, while increasing the average volume voided. The onset of pharmacological action of tolterodine is < 1 hour and therapeutic efficacy is maintained during long term treatment. In comparative trials, tolterodine and oxybutynin are equivalent in terms of efficacy. However, tolterodine is significantly better tolerated than oxybutynin, particularly with respect to the incidence and severity of dry mouth. No clinically relevant ECG changes have been noted with tolterodine.

引用

页码：813 / 820

页数：7

共 18 条

[1] Thomas TM, Plymatt KR, Blannin J, Prevalence of urinary incontinence, BMJ, 81, pp. 1242-5, (1980)
[2] Cardozo LD, Stanton SL, Genuine stress incontinence and detrusor instability — a review of 200 patients, Br J Obstet Gynaecol, 87, pp. 184-90, (1980)
[3] Andersson KE, Current concepts in the treatment of disorders of micturition, Drugs, 35, pp. 477-94, (1988)
[4] Nilvebrant L, Andersson K-E, Gillberg P-G, Tolterodine — a new bladder-selective antimuscarinic agent, Eur J Pharmacol, 327, pp. 195-207, (1997)
[5] Nilvebrant L, Hallen B, Larsson G, Tolterodine — a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data, Life Sci, 60, pp. 1129-36, (1997)
[6] Nilvebrant L, Sundquist S, Gillberg P-G, Tolterodine is not subtype (m1-m5) selective but exhibits functional bladder selectivity in vivo, Neurourol Urodyn, 15, pp. 310-1, (1996)
[7] Nilvebrant L, Gillberg P-G, Sparf B, Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine, Pharmacol Toxicol, 81, pp. 169-72, (1997)
[8] Naerger H, Fry CH, Nilverbrant L, Effect of tolterodine on electrically induced contractions of isolated human detrusor muscle from stable and unstable bladders, Neurourol Urodyn, 14, pp. 524-6, (1995)
[9] Brynne N, Stahl MMS, Hallen B, Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity, Int J Clin Pharmacol Ther, 35, pp. 287-95, (1997)
[10] Stahl MMS, Ekstrom B, Sparf B, Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity, Neurourol Urodyn, 14, 6, pp. 647-55, (1995)

← 1 2 →